NASDAQ:PULM - Pulmatrix Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$0.2446 0.00 (0.00 %)
(As of 01/18/2019 04:00 PM ET)
Previous Close$0.2446
Today's Range$0.2426 - $0.2651
52-Week Range$0.20 - $2.17
Volume192,035 shs
Average Volume369,481 shs
Market Capitalization$12.20 million
P/E Ratio-0.26
Dividend YieldN/A
Beta2.45
Pulmatrix, Inc., a clinical stage biopharmaceutical company, develops inhaled therapies to address serious pulmonary diseases using its inhaled Small Particles Easily Respirable and Emitted (iSPERSE) technology. Its proprietary product pipeline focuses on advancing treatments for serious lung diseases, including Pulmazole, an inhaled anti-fungal for patients with allergic bronchopulmonary aspergillosis; and PUR1800, kinase inhibitor for patients with obstructive lung diseases, including asthma and chronic obstructive pulmonary disease (COPD). The company is also involved in developing PUR0200, a reformulation of an existing long-acting antimuscarinic agent that has completed Phase Ib clinical development, which blocks the effects of acetylcholine on muscarinic receptors to reverse airway obstruction in COPD patients. It has a license agreement with RespiVert Ltd. to develop kinase inhibitor for access to a portfolio of novel drug candidates; and a partnership agreement with Vectura Group plc to develop its drug candidate. Pulmatrix, Inc. was founded in 2003 and is headquartered in Lexington, Massachusetts.

Receive PULM News and Ratings via Email

Sign-up to receive the latest news and ratings for PULM and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:PULM
CUSIPN/A
Phone781-357-2333

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$340,000.00
Book Value$0.48 per share

Profitability

Net Income$-18,050,000.00

Miscellaneous

Employees24
Market Cap$12.20 million
OptionableOptionable

Pulmatrix (NASDAQ:PULM) Frequently Asked Questions

What is Pulmatrix's stock symbol?

Pulmatrix trades on the NASDAQ under the ticker symbol "PULM."

How were Pulmatrix's earnings last quarter?

Pulmatrix Inc (NASDAQ:PULM) issued its quarterly earnings results on Wednesday, November, 14th. The biotechnology company reported ($0.10) earnings per share for the quarter, topping the consensus estimate of ($0.14) by $0.04. View Pulmatrix's Earnings History.

When is Pulmatrix's next earnings date?

Pulmatrix is scheduled to release their next quarterly earnings announcement on Tuesday, March 12th 2019. View Earnings Estimates for Pulmatrix.

What price target have analysts set for PULM?

1 Wall Street analysts have issued twelve-month price targets for Pulmatrix's shares. Their predictions range from $3.00 to $3.00. On average, they expect Pulmatrix's stock price to reach $3.00 in the next year. This suggests a possible upside of 1,126.5% from the stock's current price. View Analyst Price Targets for Pulmatrix.

What is the consensus analysts' recommendation for Pulmatrix?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Pulmatrix in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Pulmatrix.

Has Pulmatrix been receiving favorable news coverage?

News headlines about PULM stock have trended somewhat positive on Saturday, according to InfoTrie Sentiment. The research group identifies negative and positive news coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. Pulmatrix earned a media sentiment score of 0.9 on InfoTrie's scale. They also assigned media headlines about the biotechnology company a news buzz of 2.0 out of 10, indicating that recent news coverage is very unlikely to have an effect on the company's share price in the next few days.

Who are some of Pulmatrix's key competitors?

Who are Pulmatrix's key executives?

Pulmatrix's management team includes the folowing people:
  • Dr. Robert W. Clarke, CEO, Pres & Director (Age 50)
  • Mr. Teofilo David Raad, Chief Bus. Officer (Age 49)
  • Dr. James M. Roach, Chief Medical Officer (Age 59)
  • Dr. Robert S. Langer Jr., Founder & Member of Scientific Advisory Board (Age 70)
  • Prof. David A. Edwards, Founder & Member of Scientific Advisory Board (Age 58)

How do I buy shares of Pulmatrix?

Shares of PULM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Pulmatrix's stock price today?

One share of PULM stock can currently be purchased for approximately $0.2446.

How big of a company is Pulmatrix?

Pulmatrix has a market capitalization of $12.20 million and generates $340,000.00 in revenue each year. The biotechnology company earns $-18,050,000.00 in net income (profit) each year or ($0.93) on an earnings per share basis. Pulmatrix employs 24 workers across the globe.

What is Pulmatrix's official website?

The official website for Pulmatrix is http://www.pulmatrix.com.

How can I contact Pulmatrix?

Pulmatrix's mailing address is 99 HAYDEN AVENUE SUITE 390, LEXINGTON MA, 02421. The biotechnology company can be reached via phone at 781-357-2333 or via email at [email protected]


MarketBeat Community Rating for Pulmatrix (NASDAQ PULM)

Community Ranking:  2.9 out of 5 (star star)
Outperform Votes:  101 (Vote Outperform)
Underperform Votes:  72 (Vote Underperform)
Total Votes:  173
MarketBeat's community ratings are surveys of what our community members think about Pulmatrix and other stocks. Vote "Outperform" if you believe PULM will outperform the S&P 500 over the long term. Vote "Underperform" if you believe PULM will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 1/19/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel